BACKGROUND: Mutations in the tau gene have been reported in families with frontotemporal dementia (FTD) linked to chromosome 17. It remains uncertain how commonly such mutations are found in patients with FTD or non-Alzheimer dementia with or without a positive family history. OBJECTIVE: To determine the frequency of tau mutations in patients with non-Alzheimer dementia. PATIENTS AND METHODS: One hundred one patients with non-Alzheimer, nonvascular dementia, most thought to have FTD. Of these, 57 had a positive family history of dementia. Neuropathologic findings were available in 32. The tau gene was sequenced for all exons including flanking intronic DNA, portions of the 3' and 5' untranslated regions, and at least 146 base pairs in the intron following exon 10. RESULTS: Overall, the frequency of the tau mutations was low, being 5.9% (6/101) in the entire group. No mutations were found in the 44 sporadic cases. However, 6 (10.5%) of the 57 familial cases and 4 (33%) of the 12 familial cases with tau pathologic findings had mutations in the tau gene. The most common mutation was P301L. CONCLUSIONS: We conclude that tau mutations are uncommon in a neurology referral population with non-Alzheimer dementia, even in those with a clinical diagnosis of FTD. However, a positive family history and/or tau pathologic findings increase the likelihood of a tau mutation. There must be other genetic and nongenetic causes of FTD and non-Alzheimer dementia, similar to the etiologic heterogeneity present in Alzheimer disease.
BACKGROUND: Mutations in the tau gene have been reported in families with frontotemporal dementia (FTD) linked to chromosome 17. It remains uncertain how commonly such mutations are found in patients with FTD or non-Alzheimer dementia with or without a positive family history. OBJECTIVE: To determine the frequency of tau mutations in patients with non-Alzheimer dementia. PATIENTS AND METHODS: One hundred one patients with non-Alzheimer, nonvascular dementia, most thought to have FTD. Of these, 57 had a positive family history of dementia. Neuropathologic findings were available in 32. The tau gene was sequenced for all exons including flanking intronic DNA, portions of the 3' and 5' untranslated regions, and at least 146 base pairs in the intron following exon 10. RESULTS: Overall, the frequency of the tau mutations was low, being 5.9% (6/101) in the entire group. No mutations were found in the 44 sporadic cases. However, 6 (10.5%) of the 57 familial cases and 4 (33%) of the 12 familial cases with tau pathologic findings had mutations in the tau gene. The most common mutation was P301L. CONCLUSIONS: We conclude that tau mutations are uncommon in a neurology referral population with non-Alzheimer dementia, even in those with a clinical diagnosis of FTD. However, a positive family history and/or tau pathologic findings increase the likelihood of a tau mutation. There must be other genetic and nongenetic causes of FTD and non-Alzheimer dementia, similar to the etiologic heterogeneity present in Alzheimer disease.
Authors: Cathy Andorfer; Christopher M Acker; Yvonne Kress; Patrick R Hof; Karen Duff; Peter Davies Journal: J Neurosci Date: 2005-06-01 Impact factor: 6.167
Authors: Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey Journal: Cell Mol Life Sci Date: 2015-02-11 Impact factor: 9.261
Authors: A B Rocher; J L Crimins; J M Amatrudo; M S Kinson; M A Todd-Brown; J Lewis; J I Luebke Journal: Exp Neurol Date: 2009-08-07 Impact factor: 5.330
Authors: Leonel T Takada; Valeria S Bahia; Henrique C Guimarães; Thais V M M Costa; Thiago C Vale; Roberta D Rodriguez; Fabio H G Porto; João C B Machado; Rogério G Beato; Karolina G Cesar; Jerusa Smid; Camila F Nascimento; Lea T Grinberg; Sonia M D Brucki; Jessica R Maximino; Sarah T Camargos; Gerson Chadi; Paulo Caramelli; Ricardo Nitrini Journal: Alzheimer Dis Assoc Disord Date: 2016 Oct-Dec Impact factor: 2.703
Authors: Anna-Lotta Kaivorinne; Johanna Krüger; Katja Kuivaniemi; Hannu Tuominen; Virpi Moilanen; Kari Majamaa; Anne M Remes Journal: BMC Neurol Date: 2008-12-17 Impact factor: 2.474